Immune checkpoint inhibitors have transformed frontline care for metastatic melanoma, but a substantial proportion of patients do not achieve durable disease control, which leaves a clear unmet need after progression.

This segment focuses on first-line induction therapy for extensive-stage small cell lung cancer. Panelists explain why carboplatin plus etoposide remains the preferred chemotherapy backbone for most patients alongside a PD-L1 inhibitor.